Mallinckrodt: Time to Buy?

Mallinckrodt ( MNK ) got pummeled yesterday on reports that the FTC was set to file charges against the specialty pharmaceutical company . The headlines, however, proved to be far worse than the actual news--that Mallinckrodt would pay a $100 million fine and allow generic Acthar. Oppenheimer's Derek Archila and Marcus Ho argue that the "settlement removes [an] overhang." They explain: